In addition, our group described that miR-199b directly targets SET, a potent endogenous inhibitor of the tumor suppressor PP2A [29], thereby controlling the activation status of the SET/PP2A axis in CRC, and that its downregulation determines poor prognosis in both localized and metastatic CRC patients [30,31]. Here, SET is linked to colorectal carcinoma.